ReviewFrontiers in cell and developmental biology2026
Engrailed-1 in eccrine sweat gland development and regeneration: from evolutionary innovation to therapeutic perspectives.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional regeneration of eccrine sweat glands (ESGs) remains a major unmet need in burns and trauma, where extensive skin loss leads to permanent anhidrosis, life-threatening hyperthermia, and impaired quality of life. Here we synthesize evidence pointing to the homeodomain transcription factor Engrailed-1 (EN1) as a central regulator that coordinates ESG development across four interconnected biological functions: (1) establishing a permissive ventral limb field by repressing the WNT7A-LMX1B dorsalization pathway; (2) executing a binary fate switch that suppresses the hair follicle program while activating a pro-glandular program; (3) functioning as a quantitative rheostat whose expression levels determine ESG density-a mechanism potentiated by primate-specific enhancers such as ECE18; and (4) being required for the establishment of a transient eccrine niche (EDEN) that provides mesenchymal support during gland morphogenesis in mouse models. Drawing on this framework, we propose a tiered pathogenesis-regeneration model (Tiers 1-4) mapping to distinct EN1 failures: Tier 1 (ventral field loss) points to bioengineered glabrous skin substitutes; Tier 2 (lineage specification failure) guides strategies to redirect progenitor fate; Tier 3 (aborted morphogenesis) highlights the need for EDEN-like niche reconstruction; and Tier 4 (compromised adult integrity) suggests approaches to reinforce the mechanical anchor of existing glands through EN1-mediated regulation of epidermal isoform of Bullous Pemphigoid Antigen 1 (BPAG1e), a proposed function inferred from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.